Printer Friendly

IMRE ANNOUNCES PMA EXPEDITED REVIEW

 IMRE ANNOUNCES PMA EXPEDITED REVIEW
 SEATTLE, June 30 /PRNewswire/ -- The following was released today


by IMRE Corp. (NASDAQ: IMRE):
 U.S. Food and Drug Administration (FDA) stated in a letter to IMRE Corp. today that its "...Center for Devices and Radiological Health (CDRH) has considered your recent amendment to your Premarket Approval Application (PMA) requesting 'Expedited Review' status for this PMA supplement. After careful review of this request, FDA has determined that this application meets the criteria of the Office of Device Evaluation (ODE) General Program Memorandum for expedited review processing. Our decision is primarily based on the fact that use of this device (the PROSORBA|R~ column) is intended for the treatment of chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS), a life-threatening disease for which there are no satisfactory alternative therapies."
 FDA further stated, "We would like to remind you that because expedited review status has been granted, this application will now be processed in as expeditious a manner as possible and will be moved to the top of the designated reviewer's PMA application workload."
 C-TTP/HUS is an often fatal syndrome characterized by low platelet count, destruction of red blood cells and kidney failure which affects approximately 5,000 patients in the United States per year.
 IMRE Corp. is a medical products company that is the leader in the field of treatment immunoadsorption. The company's first product, the PROSORBA column, is marketed and sold for treatment of idiopathic thrombocytopenic purpura, an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases and certain cancers.
 -0- 6/30/92
 /CONTACT: Lois Yoshida of IMRE, 206-298-9400; or Ron Stabiner of The Wall Street Group, 212-888-4848, for IMRE/
 (IMRE) CO: IMRE Corp.; U.S. Food and Drug Administration ST: Washington IN: MTC SU:


SC-LM -- SE003 -- 5214 06/30/92 13:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1992
Words:309
Previous Article:STRONG EMPLOYMENT SPURS HOME-BUILDING, RETAIL AND AUTO SALES IN WESTERN N.C.
Next Article:BROCK EXPLORATION CONTINUES TO REPORT POSITIVE EARNINGS
Topics:


Related Articles
IMRE ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE
IMRE ANNOUNCES YEAR END RESULTS
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN REPORTED BY IMRE CORPORATION
IMRE CORPORATION ANNOUNCES THIRD QUARTER RESULTS
IMRE CORP. FILLS THREE SENIOR MANAGEMENT POSITIONS
IMRE AND BAXTER SIGN DISTRIBUTION AGREEMENT
IMRE CORP. ANNOUNCES FIRST QUARTER RESULTS
PAUL SELF RESIGNS AS PRESIDENT AND CHIEF OPERATING OFFICER OF IMRE CORPORATION
HARVEY J. HOYT, M.D., TO ASSUME ADDITIONAL RESPONSIBILITIES AT IMRE
SANDOZ LICENSES GRAFTSKIN FROM ORGANOGENESIS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters